These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16506302)

  • 1. A cancer drug shows promise, at a price that many can't pay.
    Berenson A
    N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
    [No Abstract]   [Full Text] [Related]  

  • 2. Genentech caps cost of cancer drug for some patients.
    Pollack A
    N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
    [No Abstract]   [Full Text] [Related]  

  • 3. [From orthoclone to denosumab, the fast growing market of monoclonal antibodies].
    Biot J; Fasano C; Dos Santos C
    Med Sci (Paris); 2009 Dec; 25(12):1177-82. PubMed ID: 20035702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 5. When the price is right.
    Nat Biotechnol; 2006 May; 24(5):473. PubMed ID: 16680108
    [No Abstract]   [Full Text] [Related]  

  • 6. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmaceuticals can be cost-effective in the long run].
    Jönsson B; Wilking N
    Lakartidningen; 2010 Apr 21-27; 107(16):1081-5. PubMed ID: 20476706
    [No Abstract]   [Full Text] [Related]  

  • 8. British clinic is allowed to deny medicine; decision on cost has broad impact.
    Lyall S
    N Y Times Web; 2006 Feb; ():A10. PubMed ID: 16514743
    [No Abstract]   [Full Text] [Related]  

  • 9. PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
    Isaacs RJ; Frampton CM; Kuper-Hommel MJ
    N Z Med J; 2007 Aug; 120(1259):U2676. PubMed ID: 17721579
    [No Abstract]   [Full Text] [Related]  

  • 10. Promising drug is victim of bad business.
    Dove A
    Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA. Once on 'fast track,' avastin now derailed.
    Couzin-Frankel J; Ogale Y
    Science; 2011 Jul; 333(6039):143-4. PubMed ID: 21737712
    [No Abstract]   [Full Text] [Related]  

  • 12. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 13. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 14. Avastin hearing leads to more uncertainty over drug's future.
    Goozner M
    J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug funding. Hewitt, Herceptin and the 100m pound sterling bill PCTs can't afford to pay.
    Harding ML
    Health Serv J; 2005 Dec; 115(5985):12-3. PubMed ID: 16375100
    [No Abstract]   [Full Text] [Related]  

  • 16. Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer.
    Smith M
    J Natl Cancer Inst; 2005 Sep; 97(18):1327. PubMed ID: 16174852
    [No Abstract]   [Full Text] [Related]  

  • 17. Changing end points in breast-cancer drug approval--the Avastin story.
    D'Agostino RB
    N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
    [No Abstract]   [Full Text] [Related]  

  • 18. Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
    McLean B
    Fortune; 2000 Jan; 141(1):132-4, 135. PubMed ID: 10788044
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC).
    Mueller E
    Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.